AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Who We Are
On the way to a Global Artificial Intelligence Champ
Mission & Vision
Mission“We enable customers to succeed in a competitive market by delivering real time access to the full picture of relevant data. We continuously develop our products based on Artificial Intelligence to enable broader, deeper and faster insights and to enable more informed decision making.”
Vision“Our Vision is to be recognized by our customers as a leading provider of Artificial Intelligence based products offering best in class data crawling, aggregation, analysis and visualization solutions.”
Holger HoffmannChief Executive Officer
Holger Hoffmann is the Chief Executive Officer of Innoplexus. He brings with him over 25 years of broad international experience in Sales, Finance, Controlling, Joint Ventures, M&A, and Operations within management holdings, family-owned companies, and large industrial corporations.
Holger has the rare combination of experience in finance and sales, and due to his multilingual capability and genuine interest in diverse cultures and has developed excellent global business relationships.
Dr. Andreas HochheimerChief Operating Officer & Chief Scientific Officer
Andreas Hochheimer is the Chief Operating Officer and Chief Scientific Officer of Innoplexus. Andreas’ ambition is to leverage Artificial Intelligence (AI) and Machine Learning (ML) to translate scientific knowledge into novel therapies to tackle so far incurable diseases and transform drug discovery and development from pipeline to market.
Andreas has over 25 years professional experience in Biotechnology and the Pharmaceutical Industry as well as internationally distinguished academic institutions and universities. Previously he held executive management and corporate leadership positions at BRAIN AG, Amgen and ISAR Bioscience.
Prof. Dr. Dr. Juergen ScheeleChief Medical Officer
Prof. Dr. Dr. Juergen Scheele is the Chief Medical Officer at Innoplexus and SVP Drug Development. He brings in over 20+ years of expertise in drug development and discovery. Prior to joining Innoplexus, Jürgen has held various senior positions such as Merck Global Clinical Development Leader for Tepotinib and other molecules, Global Development Leader at Roche Basel and Medical Director Micromet/ Amgen.
Jürgen has an extensive research background having received a PhD in Biochemistry/Molecular Biology from UC San Diego and the Salk Institute as well as a Master of Science in Chemistry from UC San Diego.
Dr. med. Werner SezSVP – Translational Science
Werner is the SVP – Translational Science at Innoplexus. He brings more than 28 years of expertise, primarily in early stage clinical development, biomarkers, bioimaging and drug safety evaluation.
His key expertise lies in clinical and pre-clinical studies for autoimmune diseases, cardiovascular, respiratory and renal indications as well as all kinds of ligand-binding assay development, validation and application.
Werner is an MD from Goethe University, Germany.
Abhijit KeskarSVP – Technology
Abhijit Keskar is Senior Vice President at Innoplexus, AG, where he is responsible for technology strategy, DevOps and innovation. He has 25 US Patent applications (with 16 granted so far) in the areas of Blockchain, AI and Tech. In the past, Abhijit held senior leadership positions in product companies like SAS, Majesco, before working for a startup. Abhijit has 20+ years of experience in product engineering and implementations. He is a recipient of the Exceptional Innovator Award from Basck, UK. This includes various areas like high-availability systems, analytics, data science, machine learning, AI, and blockchain.
Abhijit completed B.Tech from IIT Bombay and management from IIM Bangalore.
Dr. Gunjan BHARDWAJFounder
Gunjan is the Founder of Innoplexus and led the company as its CEO until 31st October 2022. He is an adjunct professor at Frankfurt School of Finance and management and Pforzheim University, Germany. He is an Ex BCG, EY who studied at IIT Bombay, MIT, Pforzheim University and European Business School. He has 18+ patents related to AI & Blockchain.
He published 2 books in Branding and Drug Discovery respectively as well as a number of publications in Harvard Business Review, Journal of Service Research, MIT Sloan Review etc. He received several awards including Capital – 40 under 40 award for Young Elite Award, Handelsblatt – BCG “Future Leaders of the new Reality“ and Top 30 “Thought Leader“ Award, Germany.
Ruben King-Shaw Jr.Chairman, Supervisory Board
Ruben King-Shaw Jr. has over three decades of executive leadership experience in the healthcare technology and private equity sectors and has held C-suite positions with leading private companies. He is a Chief Strategy Officer and Member of the Executive Committee of the Board of Steward Health, LLC since 2018. He is also a Chief executive officer of Mansa Equity Partners, Inc., a private equity and investment advisory firm specializing in supporting the growth of healthcare companies.
Mr. King-Shaw served on the Obama Administration’s Medicare Program Advisory and Oversight Committee.
Mohan MurtiAttorney & Counselor at Law
Accomplished leader with over 40 years of successful experience in global business management. Demonstrated ability of revenue generation while promoting business strategy on an international basis – largely based in Europe.
Initially, nominated by the Ministry of Commerce, Government of India as India’s Representative to UNITED NATIONS-IPS, Paris and Zurich and since 1993, Director, Europe, CII, Cologne, Germany. Since 2004, Managing Director, Europe, Reliance Europe. Leadership Coach & Cross-Cultural Trainer noted for establishing team synergies.
Christina Pfaff-Benitez, LL.M. studied in Passau, Boston and Frankfurt/M. and received her Master Degree in European Law and International Economics Law from the Johann Wolfgang Goethe University.
She wrote her thesis on Dispute Resolution in the WTO with grading summa cum laude. She was a private lecturer on European economic law at the University of Applied Sciences in Frankfurt/M. and a research assistant at the Chair for public Law and International Law of Prof. Dr. Dr. Rainer Hofmann and research fellow with the Merton Center for International Economic Order (cluster of excellence) with a research focus on international investment law.
Jayant BhattMasters of Law (LL.M.)
Mr. Bhatt holds dual Masters of Law (LL.M.)from New York University, USA & National University of Singapore and is a member of the prestigious Supreme Court Bar Association and Delhi High Court Bar Association. His office caters to varied clients comprising Governmental and Non-Governmental Bodies, Multinationals, Financial Institutions and individuals in an array of matters.
Mr Bhatt besides being a practicing Advocate is also a prolific speaker at various platforms and is an individual with firm belief in greater societal good. He has a keen interest in teaching and mentoring young minds and is an advisory board member to various organizations.